Cladribine Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Cladribine Access in 2026

Cladribine (Mavenclad) remains one of the most distinctive disease-modifying therapies in the MS treatment landscape — a short-course oral immunosuppressant with durable efficacy that sets it apart from daily or monthly alternatives. But for many prescribers, getting patients started on Cladribine is more complicated than the clinical decision itself.

This briefing covers the current availability picture, the cost and access landscape, and practical tools your practice can use to reduce barriers for patients in 2026.

Timeline: Key Developments

• 1993: FDA approves IV Cladribine (Leustatin) for hairy cell leukemia
• 2010: EMA initially rejects oral Cladribine for MS; Merck withdraws application
• 2017: EMA approves Mavenclad for MS in Europe
• March 2019: FDA approves Mavenclad (oral Cladribine 10 mg tablets) for relapsing forms of MS in adults with inadequate response to, or inability to tolerate, an alternate drug
• Mid-2010s–present: Intermittent shortages of IV Cladribine (Leustatin/generics) for hairy cell leukemia
• November 2025: FDA approves generic Cladribine tablets (Apotex Inc.) — first generic alternative to Mavenclad
• March 2026: No active FDA shortage for Mavenclad; IV Cladribine supply remains intermittent

Prescribing Implications

Cladribine's unique characteristics require specific prescribing considerations:

Patient Selection

Mavenclad carries a boxed warning for malignancy risk and teratogenicity. Patient screening must include:

• Malignancy screening (current malignancy is a contraindication)
• Pregnancy testing and contraception counseling (contraindicated in pregnancy; effective contraception required during treatment and for 6 months after each course)
• Screening for HIV, active hepatitis B/C, and active tuberculosis before each treatment course
• Complete blood counts with lymphocyte differential

Monitoring Requirements

Lymphocyte counts must be monitored:

• Before initiating each treatment course (must be within normal limits before Year 1; at or above 800 cells/µL before Year 2)
• 2 and 6 months after each treatment course
• If lymphocytes drop below 500 cells/µL, active monitoring until recovery

Drug Interactions

Key interactions to manage during the 4-5 day dosing window:

• Avoid concurrent immunosuppressive or myelosuppressive therapies
• Avoid ENT1/CNT3/BCRP transporter inhibitors (e.g., diltiazem, nifedipine, ritonavir, eltrombopag, cyclosporine) during dosing days
• Avoid live or attenuated vaccines during treatment and while lymphocyte counts are suppressed
• Separate other oral medications by at least 3 hours

For comprehensive interaction details, see our Cladribine drug interactions guide.

Current Availability Picture

Oral Cladribine (Mavenclad)

Mavenclad is not on the FDA drug shortage list as of March 2026. Supply from EMD Serono appears stable. However, distribution is exclusively through specialty pharmacies, which introduces coordination delays that can disrupt treatment timing.

Generic Cladribine Tablets

The FDA approved Apotex Inc.'s generic Cladribine tablets (10 mg) in November 2025. Distribution is still ramping up through specialty pharmacy channels. Of note: brand-name Mavenclad may actually cost patients less than the generic for commercially insured patients, due to EMD Serono's copay assistance program. For uninsured patients, the generic may offer meaningful savings as pricing stabilizes.

IV Cladribine (Leustatin/Generics)

IV Cladribine for hairy cell leukemia has experienced intermittent supply disruptions since the mid-2010s. The limited manufacturer base and small patient population make this formulation vulnerable to shortage. When IV Cladribine is unavailable, hematologists may need to consider pentostatin (Nipent) or other alternatives.

Cost and Access Landscape

FormulationApproximate CostNotesMavenclad (brand)~$99,500/yearWith copay assistance: $0-$25 for eligible commercially insured patientsGeneric Cladribine tablets~$15,000-$22,000+/courseEarly pricing; may decrease as market developsIV Cladribine (generic)~$300-$7,800/courseVariable; depends on shortage status

Key insurance considerations:

• Most plans require prior authorization and step therapy (failure of 1-2 other DMTs)
• Typically classified as Tier 3 (specialty) on formularies
• Medicare Part D may cover but with higher patient cost-sharing
• EMD Serono's Mavenclad Co-pay Program is available for commercially insured patients (not government insurance)

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-facing platform to check real-time medication availability. This can help your team identify which specialty pharmacies have Cladribine in stock and reduce the time patients spend waiting.

MS LifeLines

EMD Serono's MS LifeLines (1-800-283-8088) provides practice support including:

• Prior authorization assistance
• Benefits investigation for patients
• Copay program enrollment
• Patient assistance for uninsured/underinsured patients
• MS-certified nurse support for patient education

Start Referral Forms Early

Submit specialty pharmacy referral forms and prior authorization at the time of the prescribing decision — not after. For Mavenclad, a 3-4 week lead time before the planned treatment start date is advisable.

Looking Ahead

The entry of generic Cladribine tablets into the market is the most significant development for access in 2026. While it will take time for distribution networks to mature and for pricing to fully settle, the generic represents a second source of supply and a potential cost reduction for patients without strong commercial insurance coverage.

For practices managing patients on Cladribine, the priority should be early planning: submit authorizations well ahead of treatment cycles, use tools like Medfinder to monitor availability, and connect patients with MS LifeLines early in the process.

Final Thoughts

Cladribine's clinical profile — short-course oral dosing with durable immune reconstitution — makes it a unique and valuable option in the MS treatment toolkit. The access challenges, while real, are increasingly manageable with the right planning and resources. The 2025 generic approval, manufacturer support programs, and real-time pharmacy tools are all working to narrow the gap between prescription and patient access.

For a patient-facing version of this information, see our Cladribine shortage update for patients. For provider guidance on helping patients locate medication, visit our provider's guide to finding Cladribine in stock.